Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2001, p. 1036-1041, Vol. 39, No. 3
School of Science, University of Western
Sydney, Nepean, Kingswood, New South Wales,
2747,1 Fort Dodge Australia Pty
Limited, Baulkham Hills, New South Wales, 2153,2
and Veterinary Pathology Services Pty Limited, Glenside,
South Australia 5064,3 Australia
Received 8 September 2000/Returned for modification 5 November
2000/Accepted 21 December 2000
A nested PCR (nPCR) assay for the detection of canine
coronavirus (CCV) in fecal samples is described. The target sequence for the assay was a 514-bp fragment within the spike (S) glycoprotein gene. The sensitivity of the assay is extremely high, detecting as
little as 25 50% tissue culture infective doses per g of unprocessed feces. A clinical trial using dogs challenged orally with CCV SA4 and
CCV NVSL was used to compare viral isolation and the nPCR assay as
detection techniques over a 2-week period of infection. Virus isolation
detected CCV shedding from day 4 to 9 postchallenge, while the nPCR
assay detected CCV shedding from day 4 to 13 postchallenge. Cloning and
sequencing of the nPCR assay product enabled investigation of the
evolutionary relationships between strains within the S gene. The
simple and rapid procedure described here makes this assay an ideal
alternative technique to electron microscopy and viral isolation in
cell culture for detection of CCV shedding in feces. The described
assay also provides a method of identifying new strains of CCV without
the complicated and time-consuming practice of raising antibodies to
individual strains. This is illustrated by the identification, for the
first time, of an Australian isolate of CCV (UWSMN-1).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1036-1041.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Canine Coronavirus Strains from Feces
by S Gene Nested PCR and Molecular Characterization of a New
Australian Isolate
*
Corresponding author. Present address: Development
Group, Cancer Research Program, The Garvan Institute of Medical
Research, St. Vincent's Hospital, Sydney, New South Wales 2010, Australia. Phone: 61 2 92958343. Fax: 61 2 92958321. E-mail:
m.naylor{at}garvan.unsw.edu.au.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|